Phytanix Bio, SPAC Company Chain Bridge I Enter Definitive Business Combination Agreement; Combined Company To Be Named Phytanix Inc.
Phytanix Bio, SPAC Company Chain Bridge I Enter Definitive Business Combination Agreement; Combined Company To Be Named Phytanix Inc.
Phytanix Bio、SPAC公司Chain Bridge I簽署最終業務合併協議；合併後的公司將命名爲Phytanix Inc。
Upon closing of the transaction, expected to occur in the fourth quarter of 2024, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "PHYX."
預計交易將於2024年第四季度完成，合併後的公司將命名爲Phytanix Inc.，其普通股預計將在納斯達克資本市場上以“PHYX”作爲逐筆明細標的上市。
Phytanix is pioneering a new and innovative approach in the development of cannabinoid and cannabinoid-like medicines.
Phytanix正在開發新型創新藥物，以大麻素和類大麻素爲基礎。
The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close
該交易反映了Phytanix Bio 5800萬美元的預交易估值，以及承擔的1700萬美元優先股和440萬美元短期債務，這將在交易結束時轉換爲可轉換優先股。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間